Abstract
Background: Tobacco smoking is the largest preventable cause of morbidity and premature mortality in the world. Although its medical consequences are well documented, 20–50% of the population even in developed countries remain tobacco smokers. The drugs presently used in smoking cessation have limited efficiency and, therefore, there is a need for alternative and improved treatments. One novel approach in this regard may be provided by immunization against nicotine. Objective: The present study in male Wistar rats investigated if active immunization with a novel nicotine immunogen, IP18-KLH, may generate nicotine-selective antibodies and, furthermore, whether this treatment might prevent nicotine from exerting its stimulating effect on the mesolimbic, dopaminergic reward system in the brain. Methods: Enzyme-linked immunosorbent assay (ELISA) was used to determine the titer of nicotine antibodies in plasma after immunization with IP18-KLH in Freund’s adjuvant. Competitive ELISA was used to assess the selectivity of the antibodies. Finally, we used in vivo voltammetry to investigate whether active immunization with IP18-KLH could prevent nicotine-induced dopamine release in the shell of nucleus accumbens (NACshell). Results: The present study shows that active immunization with IP18-KLH generates antibodies that are highly selective for nicotine. Furthermore, immunization with IP18-KLH prevented the nicotine-induced increase in dopamine release in the NACshell, a biochemical correlate to the rewarding properties of nicotine. Conclusions: Active immunization with IP18-KLH prevents a central effect of nicotine that is considered critical for the induction of nicotine dependence. Consequently, active immunization may provide long-term protection against initiation of tobacco dependence, an effect that may prove particularly advantageous in relapse prevention.
References
1.
US Department of Health and Human Services: The Health Consequences of Smoking: Nicotine Addiction. A Report of the Surgeon General. DHHS Publ. 1988;88-8406.
2.
Peto R: Smoking and death: The past 40 years and the next 40. BMJ 1994;309:937–939.
3.
Henningfield JE: Pharmacologic basis and treatment of cigarette smoking. J Clin Psychiatry 1984;45:24–34.
4.
Fagerström KO: Efficacy of nicotine chewing gum: A review; in Pomerleau OF, Pomerleau CS (eds): Nicotine Replacement: A Critical Evaluation. New York, Liss, 1988, pp 109–128.
5.
Stolerman IP, Goldfarb T, Fink R, Jarvik ME: Influencing cigarette smoking with nicotine antagonists. Psychopharmacologia 1973;28:247–259.
6.
Corrigall WA, Coen KM: Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl) 1989;99:473–478.
7.
Malin DH, Lake JR, Newlin-Maultsby P, Roberts LK, Lanier JG, Carter VA, Cunningham JS, Wilson OB: Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav 1992;43:779–784.
8.
Hildebrand BE, Nomikos GG, Bondjers C, Nisell M, Svensson TH: Behavioral manifestations of the nicotine abstinence syndrome in the rat: Peripheral versus central mechanisms. Psychopharmacology (Berl) 1997;129:348–356.
9.
Epping-Jordan MP, Watkins SS, Koob GF, Markou A: Dramatic decreases in brain reward function during nicotine withdrawal. Nature 1998;393:76–79.
10.
Fibiger HC, Phillips AG: Reward, motivation and cognition: Psychobiology of the mesotelencephalic dopamine systems; in Bloom FE (ed): Handbook of Physiology. Section I. The Nervous System IV. Bethesda, American Physiological Society, 1986, pp 647–675.
11.
Grenhoff J, Aston-Jones G, Svensson TH: Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand 1986;128:351–358.
12.
Grenhoff J, Svensson TH: Selective stimulation of limbic dopamine activity by nicotine. Acta Physiol Scand 1988;133:595–596.
13.
Imperato A, Mulas A, Di Chiara G: Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 1986;132:337–338.
14.
Nisell M, Nomikos GG, Svensson TH: Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol Toxicol 1994;75:348–352.
15.
Nisell M, Marcus M, Nomikos GG, Svensson TH: Differential effects of acute and chronic nicotine on dopamine output in the core and shell of the rat nucleus accumbens. J Neural Transm 1997;104:1–10.
16.
Deutch AY, Cameron DS: Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience 1992;46:49–56.
17.
Deutch AY: Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: Implications for schizophrenia and Parkinson’s disease. J Neural Transm Gen Sect 1993;91:197–221.
18.
Corrigall WA, Franklin KB, Coen KM, Clarke PB: The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 1992;107:285–289.
19.
Silagy C, Lancaster T, Stead L, Mant D, Fowler G: The Cochrane Library, 3. Oxford, Update Software, 2001.
20.
Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685–691.
21.
Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR: Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 1974;252:708–710.
22.
Carrera MR, Ashley JA, Parsons LH, Wirsching P, Koob GF, Janda KD: Suppression of psychoactive effects of cocaine by active immunization. Nature 1995;378:727–730.
23.
Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ, French TL, Thompson TL, Schad VC, Greenstein JL, Gefter ML, Exley MA, Swain PA, Briner TJ: Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996;2:1129–1132.
24.
Matsushita H, Noguchi M, Tamaki E: Conjugate of bovine serum albumin with nicotine. Biochem Biophys Res Commun 1974;57:1006–1010.
25.
Matsuyama H, Tamada T, Ishiguro T, Muranaka H, Matsukura S, Sakamoto N, Imura H: Radioimmunoassay of nicotine. Biochem Biophys Res Commun 1975;64:574–580.
26.
Castro A, Prieto I: Nicotine antibody production: Comparison of two nicotine conjugates in different animal species. Biochem Biophys Res Commun 1975;67:583–589.
27.
Svensson TH, Johansson AM: Hapten-carrier protein conjugates for treatment of nicotine dependence. Patent WO 99/61054, 1999.
28.
Gonon F, Buda M, Pujol JF: Treated carbon fiber electrodes for measuring catechols and ascorbic acid; in Marsden CA (ed): Measurement of Neurotransmitter Release in vivo. Chichester, Wiley, 1984, pp 153–171.
29.
Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates, ed 2. London, Academic Press, 1986.
30.
Gonon FG: Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 1988;24:19–28.
31.
Roitt IM, Brostoff J, Male DK: Immunology, ed 3. London, Mosby-Year Book Europe, 1993, pp 7:14–7:15.
32.
Bardo MT, Green TA, Crooks PA, Dwoskin LP: Nornicotine is self-administered intravenously by rats. Psychopharmacology (Berl) 1999;146:290–296.
33.
Benowitz NL, Jacob PI, Fong I, Gupta S: Nicotine metabolic profile in man: Comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 1994;268:296–303.
34.
Benowitz NL, Kuyt F, Jacob PI, Jones RT, Osman AL: Cotinine disposition and effects. Clin Pharmacol Ther 1983;34:604–611.
35.
Barnes PJ, Ind PW, Brown MJ: Plasma histamine and catecholamines in stable asthmatic subjects. Clin Sci (Colch) 1982;62:661–665.
36.
Kågedal B, Goldstein DS: Catecholamines and their metabolites. J Chromatogr 1988;429:177–233.
37.
Croonenberghs J, Delmeire L, Verkerk R, Lin AH, Meskal A, Neels H, Van der Planken M, Scharpe S, Deboutte D, Pison G, Maes M: Peripheral markers of serotonergic and noradrenergic function in post-pubertal, Caucasian males with autistic disorder. Neuropsychopharmacology 2000;22:275–283.
38.
Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR, Milstein JR, Basham LE, Coy RT, Moon JW, Naso R, Fattom A: A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000;65:191–198.
39.
Benowitz NL, Jacob PI: Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther 1984;35:499–504.
40.
Keyler DE, Hieda Y, St Peter J, Pentel PR: Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tob Res 1999;1:241–249.
41.
Henningfield JE, Keenan RM: Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 1993;61:743–750.
42.
West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A: A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl) 2000;149:198–202.
43.
Shiffman SM, Jarvik ME: Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology (Berl) 1976;50:35–39.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
